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Research on biotechnology related firms has long been associated with the agglomeration of 
“dedicated biotechnology firms” and partners such as large corporations, research institutes 
and venture capital firms. At the same time it is acknowledged that such agglomeration trends 
may be most closely associated with medical biotechnology. This paper shows that there are 
more than 130 firms which may be classified as biotechnology related firms in Norway. 
Furthermore they are spread out throughout the country, albeit with more than half being 
located in the Eastern part. While there is indeed a great preoccupation with medical 
biotechnology also in Norway, the survey shows that two other distinct traits are present: a 
concentration of firms being focused on diagnostics and drug delivery rather than on 
therapeutics, and a focus on marine biotechnology (more than one third of the firms) within 
nutrition related products rather than or in addition to medical products. In addition to 
contributing these descriptive findings the paper thus opens up the agglomeration discussion, 
and suggests that foci on such niches as those which are prevalent in Norway may function 
with geographical distribution patterns different from those prevalent within the current 
medical biotechnology focused literature. 
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Introduction 
 
Research on the successful establishment and growth of firms has increasingly been focused 
on the relationship between internal competencies and the external environment (Powell et al. 
1996; Owen-Smith et al. 1996; Mitra 2000; Pisano 2000). Appropriate organizational 
capabilities may be interpreted as a main factor behind a firm’s success in a particular 
marketplace. However, environmental factors have also have been highlighted as essential for 
certain industries, such as biotechnology (Bartholomew 1997; Senker 1996). For “dedicated 
biotechnology firms” (DBFs),
1  proximity to partners such as large corporations or venture 
capital firms can bring external resources and competencies to the biotechnology firms 
(Bagchi-Sen 2007). In addition, due to the science-based nature of many biotechnology firms, 
the role of policy comes into the forefront in the sense of supporting the growth of an R&D 
infrastructure, securing an adequate supply of science and technology graduates, and 
smoothing the relationships with universities and public research institutes.  In sum it has 
been proposed that “networks of DBFs, venture capital firms, large corporations and research 
institutions are key in the dynamics of biotechnology” (Niosi 2003: 738). Eliasson (2000) has 
presented a similar view consisting in emphasizing the symbiotic relationships between actors, 
whereas others more recently have questioned whether this kind of agglomeration based 
development is and should be the only one for biotechnology based activities (Nightingale 
and Martin 2004). A large proportion of the literature is focused on biopharmaceuticals 
(McKelvey and Orsenigo 2006, as cited in Brink et al. 2007: 733), and although 
agglomeration may very well be beneficial for actors within biopharmaceuticals, the benefits 
may not be as evident for other biotechnology related activities such as agricultural or 
industrial biotechnology (Brink et al. 2007).  
   2
Norway is a small country in economic and population terms, and is in addition 
geographically distant from science-based centers such as e.g. the United Kingdom. This 
paper starts with the observation that there exist nevertheless biotechnology related firms in 
Norway, and subsequently describes the current activities of the Norwegian DBFs and other 
firms involved in biotechnology in terms of their product specialization areas, numbers, and 
geographical distribution. The overview also considers the relationship, if any, between 
biotechnology firms and universities and public research institutes, large corporations and 
venture capital firms. According to the first of the views cited above one could assume that 
the likelihood for the emergence of a viable network of biotechnology firms, venture capital 
firms, large corporations and research institutions is limited due to Norway’s distant location 
from science based centers and its small indigenous human and organizational population 
base. Are there nevertheless networks in this Niosi (2003) sense even in Norway, or are there 
just pockets of random activities? Does Norway’s location on the “periphery” mean that the 
existing biotechnology business in Norway is doomed to failure? Alternatively, is it actually 
the case as portrayed within public policy and parts of the industry press (NHD 1998; 
Aldridge 2005; RMV 2003: 14), that Norway displays strengths within other kinds of 
biotechnology activities such as within marine biotechnology in the sense of biotechnology 
activities being focused on organisms from the oceans,
2  and that the Norwegian case 
subsequently displays fundamentally different dynamics than the network-based dynamics 
emphasized in the literature? 
 
An extensive survey of the status quo would obviously be necessary for an in-depth 
investigation of these issues, but such a comprehensive and in-depth investigation has not 
been possible since the study has been conducted within the framework of relatively moderate 
resources.
3  The aim is rather to provide an initial and indicative overview. The paper is   3
centered on the established firms and the main part of the paper is a descriptive account of the 
product specialization areas, number of firms and employees, and geographical distribution of 
the firms. Some methodological concerns regarding which firms to include in (and exclude 
from) the study, are offered in the Appendix. There is secondly a section which discusses the 
past and current nature of public policy, including the amount of public spending on 
biotechnology research. The last section presents a summary and tries to assess some 
strengths and weaknesses of the biotechnology related activities in Norway as of today, before 
concluding with returning to the issue of whether agglomerated  networks is a key in the 
dynamics of biotechnology also in the case of Norway. 
 
Emergence and current distribution of biotechnology firms 
 
In order to describe the current status of biotechnology firms there is a need for criteria 
regarding which firms to include in such an analysis. Past overviews of biotechnology in 
Norway have estimated the number of biotechnology firms in Norway to be between 41 and 
110.
4 In contrast to extremely narrow interpretations of biotechnology activities resulting in 
low total numbers of firms falling within such interpretations, I have selected to use a wide 
interpretation of biotechnology in this study in the sense of including not only firms which 
conduct modern biotechnology as their main activity, but also firms which include 
biotechnology within their secondary activities. The disadvantage of this delimitation is lack 
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Topical distribution of biotechnology related firms 
 
Table 1 shows some key characteristics of the 134 firms in Norway which were identified in 
connection with this study as having modern biotechnology activities as the primary or 
secondary activity area. In this section we first review the product foci. The firms are divided 
into six basic product focus areas ranging from pharmaceuticals to bio-chemical production 
and broad applications, as well as a seventh additional category which consists of firms which 
focus on both therapeutic and diagnostic applications. The first segment, pharmaceuticals, is 
rather small both within the biotechnology context as well as when it comes to comparisons 
with other countries with a significant pharmaceutical industry (e.g. Sweden). In addition the 
three firms Alpharma, Weifa and Nycomed Pharma focus predominantly on conventional 
pharmaceutical approaches and not on biotechnology.  
 
[TABLE 1 ABOUT HERE] 
 
In the second segment, therapeutics, we find a considerably higher number of firms, whereas 
the number of employees is very limited.  Space restrictions prohibit describing all the firms 
in detail, but examples are Algeta (est. 1997, listed in 2007 and 23 employees as of 2006) 
developing anticancer therapeutics based on alpha particle emitting radionuclides. Biotec 
Pharmacon (est. in 1985, listed in 2005 and 33 employees as of 2006) conducts research and 
develops drug candidates within immunology and marine biotechnology focused on immune 
modulating compounds and enzymes. Lauras (est. 1998 and with 2 employees as of 2006), A-
Viral (est. 1986 and with 2 employees as of 2006) and Bionor Immuno (est. in 2000 and with 
7 employees as of 2006) all focus on HIV therapies. Clavis Pharma (est. 2001 and with 15 
employees as of 2006) is a firm based on so called Lipid Vector Technology (LVT), and relies 
on strategic alliances with established pharmaceutical firms to commercialize its discoveries.   5
Intervet Norge supplies fish vaccines and endocrine products. Pronova Biocare has developed 
the prescription drug Omacor, a lipid regulating Omega-3 based agents which was approved 
by the US FDA in 2004 (Ault 2005).  
 
In the third segment, which consists of firms active within both therapeutics and diagnostics, 
we find the firms which have perhaps been most publicized within industry and popular press 
due to the relatively large size of the segment’s firms and their high turnover (see e.g. 
Mediaplanet 2007). PhotoCure (est. 1997, listed in 2000 and with 31 employees as of 2006) 
targets selected diseases in dermatology, i.e. research related to skin diseases, and oncology, 
i.e. cancer related research,  and develops and sells devices for these diseases based on 
photodynamic technologies.  Affitech (also est. 1997 and with 31 employees as of 2006) is 
focusing on human antibody techniques. The majority of its activities are with therapeutic 
aims, but there are within the firm’s portfolio e.g., a “library” and high throughput screening 
system for antibody discovery which may justify the classification of the firm as integrating 
both therapeutic and diagnostic aims. Also within this segment are the Norwegian subsidiaries 
of US corporations GE Healthcare and Invitrogen (Invitrogen Dynal). The former traces its 
antecedents to Nygaard & Co (est. 1874) and its R&D breakthroughs within X-Ray and 
ultrasound related reagents (Amdam and Sogner 1994). Parts of this firm evolved into 
Nycomed Imaging and were then acquired by British Amersham Health in 1997, and 
subsequently by GE Healthcare. The subsidiary in Norway has 1180 employees as of as of 
2006 and continues its focus on reagents. Invitrogen Dynal (est. as Dynal Biotech in 1986 and 
since 2007 part of Invitrogen) has 175 employees In Norway as of 2006, and was originally 
founded on the basis of research conducted by the late professor Ugelstad of the University in 
Trondheim.  
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The fourth segment, diagnostics and drug delivery, is among the largest in firm count, but is at 
the same time populated with many small firms. In fact the largest firms within the segment 
are laboratories providing services to other firms (e.g. Norsk Matanalyse with 53 and as 
Telelab with 58 employees). Amongst the more specialized firms developing diagnostic 
devices or procedures we find Axis-Shield, which is headquartered in Great Britain but where 
major equity stakes are held by the Norwegian pension fund Folketrygdfondet. The 
Norwegian component of this multinational (Axis) was established in 1985 and acquired by 
Shield in 1999 for approximately 1 billion NOK. Axis-Shield acquired another Norwegian 
company, Medinor, in 1999 for 50 million NOK (CGE&Y 2000: 14-15). As of 2006, the Oslo 
subsidiary of Axis-Shield consists of 18 persons focusing on a delimited research area.
5 
Colifast (est. 1999 and with 5 employees) focuses on quick detection of bacteria in e.g. water 
and foods.  
 
In this overview we have grouped delivery-focused technologies together with diagnostics. 
These two product categories obviously differ, but the common trait is that both are important 
tasks auxiliary to therapy itself. The focus on efficient delivery techniques for 
biopharmaceuticals has intensified since the completion of the human genome project. The 
effectiveness of delivery techniques is a major influence on the effectiveness of many 
biopharmaceuticals, since their effects can vary or even be absent according to whether the 
delivered gene arrives at the targeted cell or not. Within this niche we find e.g. the Photocure 
subsidiary PCI Biotech, Innovio which focuses on gene delivery methods for DNA vaccines, 
and Genpoint (acquired by NorDiag in 2007).  
 
[BOX 1 ABOUT HERE] 
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The fifth segment, bio-informatics, is populated by seven highly specialized bioinformatics 
firms including Pubgene (established in 2001 and with 8 employees as of 2006), Sencel (est. 
2001, 7 employees) and Interagon (est. 2002, 2 employees) which is a spin-off of one of the 
most renowned ICT firms in Norway, Fast Search and Transfer. The sixth segment, breeding 
and biobanks, consist of 10 firms including Genomar (formerly Biosoft, est. in 1996 and with 
5 employees) is a firm established by academics from the Veterinary College in Oslo. The 
business idea initially focused on Atlantic salmon, but has since developed into targeting 
other breeds as well, such as the tropical tilapia fish, and much of its business now is 
conducted overseas. Additional firms within this segment include Aqua Gen, Bovibank, Geno 
and Norsvin, where the former focuses on marine species and the three latter on agricultural 
livestock.  
 
The last segment is bio-chemical production and broad applications, and is thus somewhat 
heterogeneous in its nature since it spans from industrial waste mechanisms to production of 
livestock feeds and human alimentation ingredients. Marine biotechnology firms dominate 
this segment in Norway in terms of firm and employee numbers. Norwegian firms appear to 
have entered nutraceuticals, i.e. foods claimed to have a medicinal effect on human health, in 
part because of possibilities for more sophisticated usage of marine material, as well as the 
potential for exploiting byproducts from fisheries and aquaculture. Aker Biomarine focuses 
on developing bioactive lipids (fatty acids) for the food and feed industry. Advanced 
Biopolymers focuses on chitosan-based products, and Firmenich, which was originally a 
pourely domestic firm but which is now part of a Swiss multinational, focuses on flavor 
ingredients and nutraceuticals extracted from marine sources. FMC Biopolymer, a subsidiary 
of the multinational firm with the same name (est. 1999 and with 175 employees in Norway as 
of 2006), is also predominantly focusing on marine biotechnology in its Norway based   8
activities and acquired as a part of this focus during the 1990s two firms originally spun off 
from Norsk Hydro. Several other firms specialize in development and production of animal 
feed from marine bases, such as Akva-Ren, Calanus and Eximo. A minority of firms such as 
Nutri Pharma and Biolink focus on non-marine ingredients.  
 
The remaining firms within this heterogeneous segment include Diatec producing monoclonal 
antibodies for use in medical research, and several firms focusing on industrial applications.  
They include Biosentrum (est. 1997), which is a contract research and manufacturing firm 
within fermentation and has had projects regarding e.g. biopolymers for secondary oil 
extraction, biosurfactants for use in bioremediation, fish vaccines and organic acids, and 
BioProtein (est. 2007 but in many ways a re-establishment of another firm est. in the 1980s) 
extracting protein from natural gas.  
 
Pattern of emergence of biotechnology related firms 
 
Having described segment by segment as for activities we will describe the pattern of 
emergence in some detail while trying to distinguish not only between segments, as above, 
but also between marine biotechnology and other applications.  
 
[FIGURE 1 ABOUT HERE] 
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38 percent of the firms were established before 1996 (Fig. 1), although there is some 
discrepancy between segments as for the ratios of pre-1996 establishments (Table 2). Within 
the pharmaceutical and therapeutic/diagnostic segments all seven firms were established prior 
to 1996. Moreover and as mentioned in the preceding section, for one of these firms (GE 
Healthcare) the predecessor dates back to Nygaard & Co (est. 1874). When it comes to bio-
production and broad applications the pre-1996 firm population of 20 firms stands out, and 
may be explained by a considerable ratio of firms within marine biotechnology which already 
existed prior to 1997 within e.g. fish processing or aquaculture related feed production. One 
prominent example is the firm Pronova Biocare, which was established in its present form in 
1992, but builds on a predecessor established in 1917. Within diagnostics there were indeed 
11 firms already established by 1996, but the high increase in the period 1998-2000 with 17 
additional firms is noteworthy. One explanation for this sharp increase is the foreign 
acquisition of Nycomed Imaging in 1997 mentioned in the preceding section and the 
subsequent decision to establish or participate in start-ups by several former Nycomed 
Imaging employees (Grønning et al 2006). Still another category with a strong pre-1997 
existence is breeding and biobanks. Two of the seven pre-1997 firms are, however, 
agriculture related firms specializing in cattle and pork insemination and breeding programs. 
As for the two remaining segments we see from Table 2 that therapeutics is spread out rather 
evenly, whereas bioinformatics is of a relatively recent origin.  
 
Turning now to the distribution between marine biotechnology (“Blue biotechnology”) and 
other fields the situation is heavily influenced by the phenomenon mentioned in connection 
with the emergence of bio-production and broad application firms, in other words the pre-
1997 existence of fisheries and aquaculture related firms (Fig. 2).  There is a total of 49 firms 
categorized as “Blue”, and 20 of these are pre-1997: 11 within bio-production and broad   10
applications, five within breeding/biobanks, and three within therapeutics (only three firms). 
As for the period 1997-2007 the internal distribution of “Blue” firms is led by 23 firms within 
bio-production and broad applications, something which perhaps is interpretable by additional 
actors seeing the possibilities in the development of fish oils based ingredients and additives. 
The remaining six firms in the 1997-2007 period are within the therapeutics segment. 
 
Geographical distribution of firms 
 
As for regional concentration within the Norwegian biotechnology industry, the Eastern part 
of Norway stands out as the major agglomeration with 74 firms (Fig. 3), at the same time as 
the proportion of “Blue” firms is lowest here. Although a majority of firms (54 firms) are 
located in Oslo city or its environs (the municipalities Ås, Bærum, Skedsmo and Asker), it 
should be noted, however, that the other 20 firms in the Eastern part are located at distances of 
up to ca. 150 kilometers from Oslo. Western and Northern Norway has 27 and 21 firms 
respectively, and the ratio of “blue” firms is markedly higher in the Northern part. This is 
indeed the region where aquaculture and fisheries has the longest traditions, and the higher 
ratio of non-“blue” firms in the Western part is attributable in part to the medical research 
being conducted at the University of Bergen and Haukeland Hospital. The central part where 
the science and technology university of Norway is located has, perhaps surprisingly, very 
few firms. One should note, however, that there in the past have been spin-offs from this 
university (e.g. the current Invitrogen Dynal) where the actual firm was established elsewhere.  
 
[FIGURE 3 ABOUT HERE] 
 
As for networks and organizations there exists at the national level a Norwegian Bioindustry 
Association (est. 2001), which is part of the Employers’ Federation division for process   11
industries. The Association holds regular meetings (usually held in Oslo) about trends within 
the industry and acts as a lobbying organization.  Another organization called Biomarine 
Forum (i.e. Biomarint Forum) tries to coordinate actors within the at biomarine business 
cluster in order to stimulate cooperation between sectors and improve framework conditions 
for the industry, and the Norwegian NanoMedicine Network (est. 2007) aims to gather 
research, industry and public administration within the nanomedicine field..  
 
At the international level, Medcoast Scandinavia (est. 2004)
6   supports the regional 
Gothenburg and Oslo biomedical sector in becoming “a leading biomedicine region in 
Europe” (MedCoast Scandinavia 2007: 3). The organization collaborates in turn with the local 
GothenburgBio and OsloBio (see below). Some Norwegian organizations are also engaged in 
another international network, Scanbalt.
7  
 
OsloBio aims to contribute through marketing, initiating and facilitating development projects, 
and supporting international collaboration. Oslo Teknopol acts as the secretariat for Oslo Bio. 
Oslo Bio focuses on marine life science, cancer therapy and diagnostics and wireless life 
science. The cancer therapy and diagnostics area is handled by its own organization called the 
Oslo Cancer Cluster (OCC).  As of 2007, the OCC includes as members 20 local biotech 
firms including e.g. Affitech, Algeta and Photocure, in addition to six pharmaceutical firms 
including the domestic ones and foreign firms with representation in Norway, TTOs from the 
University of Oslo and two national hospitals located in the Oslo area, and policy 
organizations such as Innovation Norway and MecCoast Scandinavia (OCC 2007).
8 The 
overall goals of the OCC seem at present to be somewhat vague, although the level of 
ambition is high in stating that the cluster is “to become the most attractive Research Based 
Industrial Cluster in Europe for Cancer Diagnostics and Treatment Innovations by   12
2015“ (OCC 2007). One step towards this goal is to apply during 2007 for Research Council 
funding as a Norwegian Centre of Expertise (OsloBio 2007). In the Eastern part of Norway 
there is in addition a network called BioInn based in the inland region of Norway 
approximately 100 kilometers from Oslo, consisting of regional colleges and firms that focus 
mainly on agricultural biotechnology.   
 
The Western (Bergen, Stavanger and the North-west coast) area has a biotechnology network 
mainly consisting in organizing regular meetings that focus on marine biotechnology entitled 
Meeting Place Marine (i.e. Møteplass Marin). Two Bergen based biomedical firms also are 
affiliated with the OCC.  
 
In the North (mainly the city of Tromsø) there has since 2002 been a “Biotechnology in 
Tromsø” group, discussing the premises of the biotechnology industry in this part of the 
country. The ten members represent the biotechnology industry, research, the public support 
system and regional authorities. As a prolongation of this group a project entitled Biocluster 
North (i.e. Bioklynge Nord) or Forum for Biotechnology and Aquaculture (i.e. Forum for 
bioteknologi og havbruk), has been in action as part of a larger program funded by SIVA and 
the research councikl of Norway 2004-2006 (Normann 2007). MabCent (Marine bioactives & 
drug discovery), received status as a research-driven centre innovation centre in 2006 (FKD 
2006) and is expected to serve as a nexus for increased networking activities in the region as 
well (Normann 2007).  There seem to be no comparable organizations in the central 
(Trondheim) area, apart from meetings and seminars taking place at the university in 
Trondheim.   
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Performance 
 
The distribution of biotechnology firms in Norway among industry segments discussed earlier 
should be kept in mind when assessing indicators of firm performance. The greatest need for 
protection in the form of patenting is in the therapeutics and therapeutics/diagnostics 
segments. Diagnostics is also an area in which IPR in the form of patents is important, 
whereas methods for ingredients production may in some cases rely on generally available 
techniques.  In addition and regardless of their segment, many firms are relatively recent in 
origin, and it is for these too early to expect a high number of patents or commercialized 
products.  
 
PCT (Patent Co-operation Treaty) patenting data indicate that Norway’s share (0,3 percent) of 
biotechnology patents
 for the year 2003 is slightly lower than Finland’s (Fig. 4). As of 2003, 
Denmark and Sweden have larger biotechnology industries and higher patenting levels. On 
average, Canada, Denmark, and the United States are among the countries in the world that 
apply for more patents in biotechnology than in other fields. For  Denmark and Canada, 




[FIGURE 4 ABOUT HERE] 
 
Another indication of the viability of Norwegian biotechnology is the fate of older 
biotechnology startup firms in Norway, specifically, the 41 firms existing as of 1999 that were 
listed by van Beuzekom (2001: 88). As of 2007, 35 of them still exist, one has been dissolved, 
four are still registered as firms but do not have any employees and are dormant at best, 
whereas one seems to have merged with another small firm.
10    14
Trends in the environment of biotechnology-related firms 
Trends in venture capital markets 
 
The OECD has observed that there have been relatively “low levels of risk capital in Norway 
as well as a scarcity of entrepreneurs” (Baygan 2003), and explained this phenomenon in 
macroeconomic terms including “large public holdings, very small pension, insurance and 
other financial entities, and low levels of evenly-distributed household wealth” (ibid.). In 
2005, the share of private equity investments in Norway was 0,24 percent of GDP, compared 
to 1,24 percent in Denmark, 0,86 percent in Sweden and 0,47 percent in Finland, whereas the 
average for Europe was 0,40 percent (EVCA Yearbook 2006, as cited in NVCA 2007). 
Restricting the comparison to biotechnology-related venture capital as a percentage of GDP 
(Table 3), Norway surpasses both amongst others Sweden, Denmark and Finland, but is far 
behind the Unite States. 
 
[TABLE 3 ABOUT HERE] 
 
Most Norwegian VC is invested domestically. In the 2000-2002 period only about 16% of the 
total VC funding went offshore,
11 mostly to the United States (56 percent) and Sweden (17 
percent) (Baygan 2003). At the same time, international investors played a minor role in the 
Norwegian VC market. During 1997-2001 they contributed about 6 percent, compared to the 
European average of approximately 50 percent of funds raised being cross-border investments 
(EVCA, 2002 as cited in Baygan 2003).   
 
[BOX 3 ABOUT HERE]   15
 
The establishment and growth of various forms of organizations related to the VC sector is 
relatively recent. The first professional venture capital firms in Norway emerged at the 
beginning of the 1980s, but it was not until 2001 that the Norwegian Venture Capital 
Association (NVCA), which is in turn a member of the European Venture Capital Association 
(EVCA), was established. As of 2005 the NVCA had 20 primary members including and 21 
associated members including the largest seed investor Statoil Innovation and the state owned 
indirect investment fund Argentum (see Box 3). The number of “Business Angels” networks 
has risen from none in 2000 via one in 2001 and seven by 2004 (EBAN 2007).  
 
The sectoral distribution of Norwegian venture capital investment is dominated by resource 
extraction industries and ICT.  Dedicated biotechnology investments accounted for only five 
percent of all Norwegian VC investments in 2005, compared to 20 percent for medical 
technology related activity (which might indeed include some biotechnology related activity 
as well), 15 percent for IT/Telecom, and 21 percent for energy (NVCA 2006). This inter-
sectoral distribution differs from those observed elsewhere in the Nordic region: Roughly 30 
percent of all Nordic VC investments (which are dominated by Swedish VC funds) in 2005 
were made in biotechnology companies, whereas energy accounted for only 2 percent. IT and 
telecom are, perhaps not surprisingly, large in Finland (24 percent), whereas Danish VC 
investments focus heavily on biotechnology, IT and telecom investments (Sørheim et al 2006: 
27).  
 
General institutional environment 
This section reviews the general institutional environment, public funding of biotechnology 
R&D, and the role of public policy in generating biotechnology-related business activities. 
Box 4 shows selected biotechnology-related events in these regards. During the late 1970s   16
and early 1980s, a number of public forums and study groups in biotechnology were 
established under official sponsorship in Norway in response to news of dramatic scientific 
advances in the field. This process was probably not very different from many other European 
countries, but in the Norwegian case the process led to an institutional distinction between 
gene technology as applied to living organisms (the Gene Technology Act of 1993) and 
biotechnology as applied within medicine (Biotechnology Act of 1994).  The distinction has 
been retained within the latest revision of the legal framework (2006-2007), with the 
government proposing a revision of the Biotechnology Act that allows for research on 
embryonic stem cells. If passed, the new legislation which will come up for voting in 
parliament during 2007 would relax somewhat the regulatory environment for biotechnology 
research.  
 
[BOX 4 ABOUT HERE] 
 
One area of continued controversy, however, concerns the commercial handling of genetic 
information obtained from the population. The 2003 Act on biobanks restricts access to the 
material stored in Norwegian public biobanks containing human material, at the same time as 
public research and business alike sees great possibilities in scientific and commercial 
exploitation of these data equal or surpassing those of Iceland’s due to the greater volume of 
data and possibilities of coupling information to other registries (Olsen 2006). Norway does, 
however, have a liberal attitude towards conventional clinical tests of drug candidates, and the 
number of clinical tests being performed in the country each year is comparatively high 
(Dobos et al. 2004). An institutional issue affecting the level of attractiveness for 
biotechnology firms to locate in Norway is the relationship to academic organizations. 
Legislation arguably has improved the biotechnology business climate. The 2002 University   17
Act amendments gave universities and colleges the primary responsibility for facilitating the 
exploitation of research, and Norwegian universities subsequently established technology 
transfer offices (TTOs). Another amendment transferred the rights to inventions made by 
employees from employees to their employing organizations (Aanstad et al. 2005: 3). These 
two changes are obviously not specific to biotechnology, but have brought Norway into line 
with other countries in Europe when it comes to potential academia – business collaboration.  
 
Level of public funding 
Norwegian biotechnology research programs have grown significantly in numbers since 1998, 
but have, with the exception of the FUGE program, been small in size (Box 4). This explains 
in part the low standings of Norwegian public research expenses within biotechnology in the 
most OECD survey referring to the year of 2003 (van Beuzekom and Arundel (2006: 19). 
When it comes to the ratio of biotechnology R&D conducted within the public sector 
(universities and PROs) in relation to the amount of R&D expenses within private firms, the 
percentage is extremely high in the case of Norway, at least through 2003. Spain and Korea, 
for example, approach the level of Norway, but these two nations are still quite far behind 
(ibid.). At the same time the absolute amount of public funding for biotechnology R&D in 
Norway is moderate by international comparisons, and lower than Finland, New Zealand and 
Denmark (the actual situation for Sweden is unknown). Compared to the ca. 75 percent of the 
R&D being financed by public means in Norway in 2003, the corresponding figure in 2005 
was more than 80 percent (ca. 960 million NOK).
 12  Biotechnology R&D expenditures by the 
public sector were 831,6 million NOK, increasing to 1, 179 billion NOK in 2005. The 
biotechnology R&D share of total public R&D was six percent in 2003, rising to 
approximately seven percent in 2005 (Sundnes and Sarpebakken 2007).   
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Human medicine and biopharmaceuticals were the largest fields of Norwegian public funding 
for biotechnology R&D in 2003 and in 2005. The University of Oslo and its associated 
hospitals are by far the largest single academic recipient of public biotechnology R&D 
funding, accounting for more than half of the expenditures. Its spending nearly doubled 
during this two-year period, with a majority of the increase accounted for by the University’s 
hospitals (Sundnes and Sarpebakken 2005, 2007).  There was an increase of 350 scientists 
participating in biotechnology research in the public sector between 2003 and 2005, 
producing a total of 1800 scientists as of 2005 (ibid.). International comparative data for 2005 
are not available, but the increased Norwegian public funding may well have raised Norway’s 
rank in international comparisons relative to 2003. Nevertheless the dominance of public 
funding within overall Norwegian R&D spending in biotechnology is likely to remain 
unaltered for the near future.  
 
Discussion and conclusion: Peripheral advantage, or just periphery? 
I conclude this survey by summarizing in the form of a SWOT (strengths, weaknesses, 
opportunities and threats) format at the level of Norwegian commercial biotechnology 
activities, and then providing some reflections on the overall current and possible future state 
of biotechnology in Norway, drawing on the framework proposed by Niosi (2003) regarding 
agglomeration benefits. 
 
A tentative assessment of the situation 
Strengths include the scientific and commercial success of several firms, which may draw 
increased attention to them and other new entrants. Patenting seems to be increasing, and 
some products have been launched or are in the process of being launched. Several highly   19
publicized Norwegian firms within diagnostics and drug delivery are believed to have 
considerable growth potential, as are others in therapeutics and marine biotechnology. These 
successful examples may serve as models for other firms considering entry into these 
segments of biotechnology. Norway also has a dominant group within diagnostics that builds 
on past strengths in medical devices. The examples of Photocure, DiaGenic and PCI Biotech 
also point towards a possible new Norwegian capability to combine predominantly academic 
knowledge about diseases and their diagnosis or treatment with commercially oriented 
electronics, in some cases reagents, and in other cases, informatics. 
 
There is considerable health-related biotechnology activity in the Oslo area. The Oslo 
concentration may also prove capable of interacting with Gothenburg-based firms and PROs, 
as well as with other firms in the Oslo region. The total amount of venture capital potentially 
available is considerable, and has a highly developed tradition for administering clinical tests 
for the pharmaceutical industry. 
 
Weaknesses include the lack of large Norwegian pharmaceutical firms, although this gap is in 
part compensated for by a strong Norwegian presence of several multinational firms such as 
AstraZeneca and GSK, that pursue both marketing and clinical tests in Norway. The large 
indigenous companies within the Norwegian innovation system have in recent years 
concentrated on their core competencies and, with some exceptions (see below) decided not to 
invest in other areas. The most prominent example of this is Norsk Hydro, which was 
involved in the start-up and expansion of several biotech firms. Norwegian venture capital 
investment is concentrated in non-biotechnology areas. There has in the past allegedly been 
little interaction within the largest group of firms focusing on diagnostics (CGE&Y 2000),   20
although this seems to be changing with the advent of thematic and regional umbrella 
organizations.  
 
Opportunities include the recent interest in and strengthening of marine biotechnology basic 
research, such as the recent establishment of the Akvaforsk research consortium and the new 
centre for this purpose in Tromsø.  State controlled biobanks may turn out to be the basis for 
future commercial activity. Competencies within diagnostics and information from biobanks 
might be combined into ingenious drug delivery technologies. Already in 2000 the 
expectations based on lessons from the  HUGO project have led to predictions about 
individualized pharmaceuticals (CGE&Y 2000: 6), and this is a new area in which Norwegian 
biotech could play a role. Within the production-based segment there are ample possibilities 
of expanding as well as refining the product lines, as companies like Aker Biomarine is doing.  
This firm is incidentally also an exception form the trend of large enterprises abstaining from 
engaging in a field like biotechnology, in that it is part of the large Aker Corporation.  
 
Although geographically dispersed among Oslo, Bergen, Trondheim and Tromsø, the cultural 
and institutional proximity of firms as well as the tradition of collaboration within Norwegian 
business may provide opportunities for enlarged networks that extend beyond the clustering at 
any specific location. The inclusion of Bergen based NorDiag in the Oslo Cancer Cluster is an 
example of this approach.  
 
Experience in “demand driven” (Goldfarb et al. 2001) collaboration might have potential for 
emulation by other firms especially within the large diagnostics and drug delivery segment. 
By generating additional values or competences at the Norwegian location, the risk for 
“hollowing out” (see below) might to a certain degree be countered.  One case in point may   21
be the example of DiaGenic, which has developed a technology that could itself be transferred 
elsewhere, but where the development process for this technology has relied on “demand 
driven” collaboration between technically and scientifically competent staff within the firm 
and scientific staff at public organizations with in-depth knowledge of specific therapeutic 
areas. Such a strong bilateral relationship may not be easily transferred, and this type of 
industry – academia collaboration, which differs from the conventional “supply driven” (ibid.) 
form.  
 
Threats include fragility of the established network. Successful innovation achieved in 
peripheral locations such as Norway may somewhat paradoxically result in the movement 
from Norway to foreign sites of key personnel or technical capabilities if the technology is 
deemed as useful at the other location. The most attractive firms, technologically speaking, 
may thus be vulnerable to “hollowing out” processes triggered by foreign acquisitions of the 
whole firm or parts thereof, although continued  activities in a wider sense through 
establishment of other, smaller firms within a similar technological specialization area seem 
to have made up for the personnel reductions within some foreign owned firms.  
 
An additional, potential threat is that the historical record of innovation policy in Norway is 
characterized by a lack of understanding at the policy level of the heterogeneous nature of 
commercial opportunities within biotechnology. Biotechnology firms and start-ups are 
referred to in most policy documents as firms that uniformly face long development times, 
high risk factors, and large capital needs (e.g. therapeutics oriented firms like Biotec 
Pharmacon).  In fact, however, a majority of Norwegian biotechnology firms belong to other 
segments, such as diagnostics and bio-chemical. There is thus a certain risk that overall   22
sectoral policies will be designed for only one type of firm, rather than developing a 
differentiated policy framework   
 
Public policies also have assumed that Norway had a special comparative advantage within 
marine biotechnology, a strength which in turn was perceived to be based on past marine 
experience like fisheries and aquaculture. There are indeed correlations between these fields, 
but vast efforts in other fields additional to the recent initiatives mentioned above seem to be 
necessary if one wants to develop marine-biotechnology based applications within drug 
development, for example.  
 
The small number of Norwegian science and technology graduates combined with limited 
immigration within these fields may pose a threat to the expansion of public and business 
R&D efforts alike.  
 
The policy initiatives have, among other things, focused on past and present research strength 
in fields such as oncology (MedCoast 2007), where Norwegian researchers appear to be much 
stronger than in fields such as biopharmaceuticals (van Beuzekom 2001: 15; Enzing et al. 
2006: 106). To maintain and strengthen Norway’s reputation as a specialized high-level 
oncology research center will require continued excellence in publication and research 
performance to exploit increased funding opportunities and overcome the negative publicity 
associated with alleged weakness within biopharmaceuticals.  
 
In Norway, policy measures and institutional frameworks have been subject to some change 
and instability within the biotechnology sector, and this may have acted as a disincentive for   23
private investment in this industry. Specialized investors are still largely absent, with the 
recent exception of the new investment fund Sarsia Innovation.  
 
Conclusions 
As concluding remarks we will now return to the proposal by Niosi (2003) regarding that 
“networks of DBFs, venture capital firms, large corporations and research institutions are key 
in the dynamics of biotechnology”. We have seen that large enterprises are to a significant 
extent absent from the Norwegian context. However, they are indirectly present in the form of 
representation, such as e.g. foreign pharmaceutical firms such as AstraZeneca and GSK 
participating in the Oslo Cancer Cluster, and at least one large domestic firm is involved in 
biotechnology. Nevertheless, the general absence of large domestic firms underscores the 
importance of initiating and maintaining networking activities such as those supported by 
Møteplass Marin, BioKlynge Nord, OsloBio and Oslo Cancer Cluster. The Niosi hypothesis is 
also open to question concerning the size and extent of the networks that are allegedly needed 
in order to deserve the label of network. In the Norwegian case one could discuss whether the 
minimum level of firm population has been reached at the national level, and whether all the 
four main Norwegian locations of Oslo, Trondheim Bergen and Tromsø should or should not 
be seen in connection as one network or as four separate networks. In the Oslo area case, the 
relationship to Gothenburg and, possibly, even further towards the Øresund region is also a 
possibility firms could consider for seeking customers or collaboration partners.  
 
In the case we cannot discern a network (or four networks) in the Niosi sense, the Norwegian 
experience is perhaps an interesting example of an alternative organizational mode. One 
element in the set-up of the Norwegian context is the significant presence of marine 
biotechnology, albeit perhaps not as dominant as one could expect based on policy predictions.   24
Also, although the medical component is strongly present in the Norwegian case, the auxiliary 
segment (diagnostics and drug delivery) is more prevalent and does not necessarily have the 
same immediate needs as therapeutics for geographical proximity to venture capital firms and 
science centers. This may also be a segment which is especially conducive towards demand 
driven collaboration forms, e.g. within engineering-oriented solutions within diagnostics. 
Similarly, demand driven – and not necessarily geographically proximate- collaboration forms 
may be more relevant than supply driven collaboration forms within biochemical production. 
Thus, perhaps in conjunction with the advances of biotechnology itself and increased 
heterogeneity of biotechnology related firms, the forces conducive to agglomeration being 
weakened? It might then after all be possible to foster a viable biotechnology industry in a 
location remote from the science based centers of the world with limited firm population, as 
well as with limited size of the domestic research organizations.  
 
A follow-up of this question will, however, have to be an issue for further research focusing 
on the Norwegian experience. The review has shown that most important events occurred 
very recently, from the mid-1990s onwards. The number of new firm establishments grew 
from 1997 onwards, and the emergence and subsequent consolidation of the biotechnology 
industry in Norway is therefore at a very early stage, although there are some indications of 
path dependence in the sense of building upon past strengths and capabilities. This 
phenomenon is discernible especially in connection with the emergence of advanced 
diagnosis and drug delivery techniques and of photo-therapeutic solutions, all of which have 
roots back to previous achievements within Norwegian industry based on reagents and 
engineering. Also, the current presence of a large number of firms within nutraceuticals would 
have been unlikely without the past capabilities in fisheries and aquaculture.  
   25
The emerging Norwegian biotechnology industry is more difficult to position within path 
dependencies in terms of the taxonomy in Wicken (2007) that described a set of layers 
consisting of sectoral groups and their geographical and institutional surroundings that range 
from small businesses focused layers to heavy industries focused layers. Large parts of the 
contemporary biotechnology industry in Norway have elements in common with high 
technology engineering, and in the case of marine biotechnology, there are commonalities 
with the natural resources extraction tradition. Moreover, the recent emergence of 
biotechnology firms has occurred simultaneously with the new the types of relationships the 
firms have developed with academic organizations, as well as simultaneously with the 
development of a venture capital market. Taking these three together, we may perhaps rather 
talk of this set of developments as a kind of “path creation” (Garud and Karnøe 2000; 
Schienstock 2004). That is, we obviously do not know at present whether and how this part of 
the Norwegian economy will develop into a dominant position, but we might be witnessing 
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Notes 
                                                 
 
1 Biotechnology is usually defined as "the application of scientific and engineering principles to the 
processing of materials by biological 
agents to provide goods and services" (van Beuzekom and Arundel 2006: 14), whereas “modern biotechnology” refers to the applications 
emerging form scientific discoveries at the genome level during the 1970s (cf. Queré 2004).  
 
2 Marine biotechnology is, as noted by Biobridge Ltd. unlike other areas of biotechnology in that it is defined in terms of its source material, 
rather than the market it serves (Biobridge Ltd, 2005, as cited in Aslesen 2005: 9). ESF's "vision for the 21st century is that marine 
biotechnology will apply advanced tools from 
molecular biology and information technology 
to a carefully selected suite of marine habitats 
and organisms represent
ing the total diversity 
of marine systems, in order to obtain novel 
genes and processes that can be turned into 
new 
products and approaches for the benefit of 
industry, biomedicine, and the sustainable use 
and management of the world’s ocean” (ESF 2001: 
4), and the foundation divides into the five different marine biotechnology  research and business sub-areas developing novel drugs; 
producing diagnostic devices for monitoring health;  discovering new types of composite materials, biopolymers and enzymes for industrial 
use; ensuring safety of aquaculture and fisheries; and providing new techniques for management of marine environments; (ibid.: 6, with 
order altered; see also Grønning et al. 2004). 
 
3 Observations serving as a foundation for the analysis were  obtained in connection with a one year project funded by the Research Council 
of Norway in 2005  (Dobos et al 2004; Grønning et al. 2004; Grønning et al. 2006), whereas the current paper itself is based on additional 
non-funded research during a half year period in 2006-2007. 
 
4 The estimates are 41 firms (Critical I 2006), 85 (Research Council of Norway according to Berntsen and Dalen 2004), ca. 75 firms (EBN 
2006), and 110 (Marvik 2005; NFR 2007). Critical I (2006) itself operates with 41 firms, whereas a more detailed overview identifying the 
firms says 42 firms (Hodgson 2006). 
 
5 Critical I (2005) reports a ca. 50 persons in staff.in 2003. 
 
6 MedCoast Scandinavia started already in 1995 through a joint venture agreement , established in April 2002 as a project, established as an 
independent member organization in November 2004, and began operating 
on the 1st of January 2005 (MedCoast Scandinavia 2007: 3-4 )  
 
7 These are BioInn (see below) and Innovation Norway.  
 
8  The local firms which are members are Affitech, Algeta, Alpharma, A-Viral, Axis-Shield, Biomolex , CancerCure, Clavis Pharma, 
DiaGenic, Lauras, Lytix Biopharma, Mole Genetics, NorChip, Nordiag, Optinose, PCI Biotech, PhotoCure, PubGene, Photosense, and Drug 
Discovery Laboratory (DDL); the pharmaceutical firms are AstraZeneca, Bristol-Meyers Squibb, GlaxoSmithKline, Merck (MSD), Pfizer 
and Roche, and the TTOs and policy organizations are Birkeland Innovasjon affiliated to the University of Oslo, MedCoast Scandinavia, 
Medinnova (the National Hospital TTO), Innovation Norway , Oslo Teknopol , IKS , and The Norwegian Radium Hospital Research 
Foundation  (OCC 2007).   
 
9 This is also the case for and Belgium (OECD 2006: 20). 
 
10 There are actually 44 firms in the list presented by van Beuzekom (2001: 88), but two are established pharmaceutical firms and one is not 
conducting biotechnology research and have been excluded form the mapping.  
 
11 Note that we are still dealing with the VC market in isolation, and thus not including the overseas stocks and bonds invest
ed in by the 
Petroleum Fund. 
 
12 It should be noted that the estimates on business R&D are not directly comparable between 2003 and 2005, since statistics until 2003 
divide between marine R&D and biotechnology R&D, whereas starting in 2005 marine biotechnology as a sub-field is to be classified as 
biotechnology.    27
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List of acronyms, abbreviations and technical terms 
Antibody: Protein used by the immune system to identify and neutralize foreign objects like 
bacteria and viruses 
CGE&Y: Cap Gemini Ernst & Young 
Dermatology: Diagnosis and treatment of diseases and tumors of the skin 
CMBN: Centre for Molecular Biology and Neuroscience (2003-2012), Bioprospecting 
platform at SINTEF in collaboration with NTNU (2004-2007),  
EBAN: European Business Angels Network  
EMBL: European Molecular Biology Laboratory 
FORNY: Sector unspecific pre-seed financing mainly given to TTOs (running)  
FUGE: Functional genomics program (2002-2011)  
GNBIO: Basic business oriented biotechnology program  (2001-2008)  
HIV: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired 
immunodeficiency syndrome (AIDS), a condition in humans in which the immune system 
begins to fail 
Lipids: Class of hydrocarbon-containing organic compounds (molecules which contain carbon) 
MABIT: Research program related to commercial. exploitation of marine resources (1998-
2008)   
Marbank/Marbio: Marine biobank and bioprospecting platform at the University of Tromsø 
(2004-2007)  
MEDKAP: Technology validation in biomedical research (terminated by 2007)  
NFR: Research council of Norway 
NHD: Ministry of trade and industry 
Nutraceuticals: Combination of the words "nutrition" and "pharmaceutical" and refers to 
foods claimed to have a medicinal effect on human health   32
NYSE: New York Stock Exchange 
Omega-3: Group of fatty acids  
Oncology: The branch of medicine that studies tumors (cancer) and seeks to understand their 
development, diagnosis, treatment, and prevention. 
OSE: Oslo Stock Exchange 
PCT: Patent Co-operation Treaty 
Peptides:  family of short molecules  which allow the creation of antibodies in animals 
without the need to purify the protein of interest 
PRO: public research organization 
PROSBIO: Industry initiated research related to biopharmaceuticals and processing industry 
(2002-2010),  
BIOT2000:  Applied research related to agricultural, aquaculture and environmental 
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Appendix: Notes on Methodology 
 
This paper is trying to provide an initial and indicative overview of biotechnology business in 
Norway as of 2006-2007, but it should as mentioned in the introduction be noted that there are 
delimitations due to space and resource restrictions. Not included is otherwise important 
information such as financial status of firms, number and type of alliances, and detailed 
history of the firms in terms of origin. what has been done is to interpret and categorize the 
population of firms which have modern biotechnology  as their primary or secondary activity. 
Firms were identified through industry sources (NorBioBase – a national database for the 
biotech industry), previously published reports (CGE&Y 2000; van Beuzekom 2001; Mabit 
2002; Hernes et al. 2004; Marvik 2005; Normann 2007) and industry press (EuroBiotech 
News, Nordic Life Science). After assessing whether the firms seemed to meet the criterion of 
being relevant to modern biotechnology (i.e. traditional biotechnology firms such as breweries 
and bakeries etc. were excluded), the firms were confirmed as indeed existing in the sense of 
having submitted publicly available records regarding address, employee numbers and 
accounts as registered in the database Purehelp.no or via alternative confirmation in the case 
of two firms which were not registered there (Kilda Biolink and Balter Medical/Photosense). As 
for employee numbers information, except for the two exception firms mentioned above for 
the sake of consistency being refereed according to the database entries although the total 
numbers used in this paper are fairly sure to be lower than actual numbers. This is because 
many start-up firms are registered with only few or no employees, and have temporary project 
staff instead of regular employees. There is a certain risk that the actual total number of firms 
is underestimating the actual situation: 10 firms have not been included due to lack of 
necessary confirmation regarding the continued existence and activities (Alnæs Marine Oils, 
Ampligéne,   Chameleon Pharma,  Cryotech Seafood, Normedica, Velomar,  Procaryo, 
ProVisage, Silfas, and TransHerba).    34
 
Neither have 11 firms referred to in relevant literature been included within the bio-chemical 
segment due to difficulties in determining whether they indeed conduct modern biotechnology 
(Biova,  Drytech,  Hordafôr,  Kavli,  Marin Lipids,  Miljøprosess,  Mills,  Nutreco,  Peter 
Møller,  Skretting and  Toro).  One originally Norwegian firm is now Icelandic and seems to 
have only very limited activity in Norway has not been included (Primex Biochemicals).  
Neither have firms owned by Norwegian capital, but located entirely abroad, been included 
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Table 1: Biotechnology-related firms in Norway (June, 2007) 
 













“Blue” Others Total    “Blue” Others    East   West   Central  North 
Pharmaceuticals 0  848  848 0 3 3 3  0 0 0
Therapeutics   224  73  297 9 16 25 18  3  2 2
Therapeutics/ 
Diagnostics  
0 1417 1417 0 4 4 4  0  0 0
Diagnostics, 
analysis and drug 
delivery  
0 305 305 0 38 38 25  8  2 3
Bio-informatics  
 
0 25 25 0 7 7 4  1  2 0
Breeding / 
biobanks 
317 69  386 5 5 10 6  0  1 3
Bio-chemical 
production etc.  
783 153 936 35 12 47 14  17  3 13
Total 1324  2890  4214 49 85 134 74  29  10  21 
Notes: For selection criteria, see appendix 1. Firm headquarters refer to office in Norway for the firms with 
foreign ownership. “Bio-chemical production etc.” includes broad applications. Employee numbers not available 
for one firm each within Bio-informatics, Diagnostics and Therapeutics, and for one firm  each within   
Breeding/biobanks and Bio-chemical production etc. the employee numbers are from other sources than 
Purehelp.no. 
Sources:  Compiled based on information from Purehelp.no (employee numbers); author’s assessment when it 




Table 2: Year of establishment of biotechnology firms in Norway divided into segments 
 
  1996> 1997  1998 1999 2000 2001 2002  2003 2004 2005
2006-
2007
T h e r a p e u t i c   5  3   11133   3  2 12
Therapeutic/  
D i a g n o s t i c     4  0   00000   0  0 00
D i a g n o s t i c     1 1  0   94443   0  1 20
B i o - i n f o r m a t i c s     0  0   00141   0  1 00
Breeding/biobanks 7  1  0 0002  0   0 00
Bio-production and  
 broad applications   20  2  2 1455  1   2 41
P h a r m a c e u t i c a l   3  0   00000   0  0 00
Sources:  Compiled based on information from Purehelp.no (except for in the case for two firms); author’s 
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Table 3: Venture capital characteristics ca. 2003 
 
 Norway  Sweden Denmark Finland Spain  UK  Canada  USA 
Total venture capital 
investments in 
biotechnology, 2001 to 
2003 combined (1) 
74  323 159  29  14 502  721 9526 
Percent of 2003 total 
venture capital in 23 
countries combined 
0.6 2.5 1.2  4.2 0.1  3.9  5.6  74.4 
Biotechnology venture 
capital investments as 
a percentage of GDP, 
2003 




327 669 240  454 NA  NA  NA NA 
Total amount invested 
2003 (2) 
239 1056  232  386 NA  NA  NA NA 
Notes. 1.  Millions USD. 2. Millions euro. Source: van Beuzekom and Arundel (2006) based on data from 















































"Blue" 2 061 57 1
Others 29 19 25 10 2
1996> 97-99 OO-O2 O3-O5 O6-O7
 










All firms 10 74 21 29
"Blue" firms  31 4 1 6 1 6
Central East North West
 

































Notes:  1.The provisional definition of biotechnology patents is   
[A01H1/00,A01H4/00,A61K38/00,A61K39/00,A61K48/00,C02F3/34,C07G(11/00,13/00,15/00), 
C07K(4/00,14/00,16/00,17/00,19/00),C12M,C12N,C12P,C12Q,C12S,G01N27/327, 
G01N33/(53*,54*,55*,57*,68,74,76,78,88,92)]. Patent counts are based on the priority date, the inventor's 
country of residence and fractional counts. 
Source: Compiled based on dataset attached to OECD (2006: 20). 
 
Fig. 4: Number of biotechnology patents
1 filed under PCT   39
Box 1: Diagenic: “Today we are somewhere in between  
being small and not being small” 
 
DiaGenic focuses on early disease detection of diseases.  It has  
got  15 employees, two post- docs and one PhD-student, leading to  
the self-assesment that “Today we are somewhere in between  
being small and not being small”. As of 2007 the two targeted  
diseases are Alzheimer’s and breast cancer. Although totally  
different, a common trait shared by the diseases is the lack of  
a “gold standard”  for their detection them. The firm has  
concentrated on getting access to blood samples with good clinical data and developing competence 
on the diseases as a basis for technical  solutions. In 2007 the firm announced the first validated 
prototypes for gene expression signature tests for the early diagnosis of the two diseases. 
 
The innovativeness of the prototype lies in its non-invasive aspect, enabling  detection of a disease  
through features examined elsewhere, in this case blood. The process for arriving at these solutions 
seems to be quite innovative as well, since the firm compensates for its lack of in-depth and 
continuously updated knowledge about the specific diseases in question by building collaboration 
with the University of Oslo.  
 




1997 - Concept discovered 
1998 - DiaGenic founded 
2000 - Full time research 
2002 - Proof of concept 
2004 - First patent granted (US/EU) 
and listed on Oslo Stock Exchange 
2005 - Scientific recognition 
2006 - Prototypes developed 
2007 - Frost & Sullivan 
Entrepreneurial Company of the 
Year Award in the European 
molecular diagnostics market . 
Announced capital expansion 
through issue of shares valued 28 
million NOK   40
Box 2: Mergers, de-mergers and acquisitions (highlights) 
 
1984 Alpharma listed NYSE. 
1995 Norsk Hydro sold out of Swedish BioInvent (acquired in 1990) 
1997 Merger between Amersham and Nycoomed Imaging (later to be acquired by GE Healthcare) 
1998 The firm Natural listed OSE. Pronova Biocare acquired all the shares in Lipro (est. 1877) based 
on cod liver oil production. 
1999 Axis-Shield listed on London/ OSE.  
2002 FMC BioPolymer acquired Pronova Biomedical, a supplier of alginates and chitosans.  
2004 Sarsia acquires majority of shares in Danish Medi-Mush. 
2005 NorDiag, Biotec Pharmacon and DiaGenic listed Oslo Stock Exchange. Dynal Biotech sold to 
Invitrogen. EPAX Sales and Production de-merged from Pronova Biocare, where Pronova focuses 
solely on the production of API/Omacor and EPAX producing Omega-3 oils for the dietary 
supplements industry. 
2007 Algeta listed OSE. Nordiag acquires Genpoint. Aker BioMarine and Pronova Biocare signed a 
letter of intent to establish develop pharmaceutical products from krill. Natural merges with Aker 
Biomarine.  
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Box 3: The special case of public investment funds 
 
State ownership in industry is relatively high in Norway, but as for investment in new start-ups, there 
is no political consensus on the appropriate approach. Part of this discussion concerns whether and to 
what degree the state should act as a direct owner in nominally private firms.  The Government 
privatized the major state-owned player in the VC market (SND Invest) in 2003/2004, consistent with 
the recommendations made in a 2002 White Paper on state ownership. SND Invest was acquired by 
what is now known as Verdane Capital funds, formerly Four Seasons funds. Another initiative was the 
Start fund established in 1998 with 50-50 private and public participation. It was discontinued in this 
form in 2004 when a private fund management firm was asked to realize the value of the portfolio. 
 
The remaining dominant state involvement in ownership as of 2007 is Argentum funds established in 
2001, which invests only in other funds and not directly in firms. Argentums is one of the largest 
investors in Verdane Capital funds as well as in Teknoinvest III which has placements in firms like 
Photocure, the AKVA group supplying technology to the fish farming industry and a medical device 
company named BioForm Medical in addition to ICT related investments such as Trolltech, Opera 
Software, Funcom, and Tandberg. 
 
Another public-private model is exemplified by Sarsia Innovation, which focuses on high-technology 
investments predominantly on a regional basis. 75% of Sarsia is owned by state investors and 25 
percent by private investors. Portfolio companies include Medi-Mush, NorDiag, Novel Diagnostics, 
TIPOgen, PlasmAcute, and UniTargetingResearch  in addition to non-biotech firms such as 
Environmental Solutions AS focusing on ship ballast water management technology and Epsis AS 
delivering services to the oil and gas industry  
 
Sources: Argentum (2005), Louët (2004), Sarsia Innovation (2007),  Teknoinvest II (2007), NHD 
(2006). 
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Box 4: Chronology of events, policies and institutional changes  
 
1970-77 Scientists at the Oslo and Bergen universities initiate research involving recombinant DNA-
technology 
1977 New method for sequencing DNA published 
1977-78  SINTEF establishes Norway’s first biotechnology group with support from research council 
1980 The corporation Amgen Inc. founded in the US 
1980-84 Series of committees on biotechnology led by Laland (1980), Kleppe (1982) and Prydz 
(1984) 
1985 Biotechnology became became one of five “main target areas” in the 1985 White Paper on 
research. Public scepticism towards biotechnology surfaced when a break-through in a research project 
on salmon  
1985-86 New national action plan / biotech became one of five ‘main target areas’ in the 1985 White 
Paper on research policy with little or no attention paid to any other aspect than the immense economic 
and 
research potential of the new technology. Increasing grants to biotechnology and research council 
action plan on biotechnology; Norway becomes member of EMBL 
1987 Norway participates in Nordic cooperation program on biotechnology 
1991 The Norwegian Biotechnology Advisory Board established. 
1993 Gene technology Act passed. White Paper on humans and biotechnology.  
1994 Biotechnology Act passed. European Laboratory for Marine Biotechnology established in Berge 
1996 Perspective analysis and action plan for biotechnology for 1995-2005 presented  
1997 Research Council presents Strategy for biotechnology 
1998 National strategy for business oriented biotechnology 
1998-2011 Series of biotechnology research programs, including large FUGE - Functional genomics 
program (2002-2011) (see complete list appended at end of paper) 
2002 SkatteFUNN tax scheme for deduction on R&D investements for SMEs instituted 
2002 University Act amendment regarding rights to inventions 
2003 Act on biobanks 
2006 Eurobarometer study shows increased optimism towards biotechnology amongst Norwegians 
2007 Amendments to Biotechnology Law scheduled to be proposed to parliament 
2008 Norway scheduled to become member of EPT 
Sources: Compiled based on Kallerud (2004), Marvik (2005) and government and research council 
information material and news releases. 
 
 